JP
NBIX icon

Jana Partners’s Neurocrine Biosciences NBIX Stock Holding History

Jana Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-181,296
Closed -$7.02M – 59
2016
Q4 		$7.02M Buy
181,296
+85,086
+88% +$3.85M 0.12% 43
2016
Q3 		$4.87M Buy
+96,210
New +$4.79M 0.09% 43

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jana Partners's NBIX Position: Q1 2017 in Review

Jana Partners sold out of Neurocrine Biosciences (NBIX) in Q1 2017, closing a stake of 181,296 shares — an estimated $7.02M sold.

Jana Partners first reported a position in NBIX in Q3 2016 and held it in 2 quarters. The position peaked at $7.02M in Q4 2016. 218 funds tracked by Wall St. Rank hold NBIX as of Q1 2017.

  • Jana Partners reported no remaining Neurocrine Biosciences position as of Q1 2017 after selling out during the quarter.
  • Jana Partners sold 181,296 Neurocrine Biosciences shares in Q1 2017, an estimated $7.02M.
  • Jana Partners first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 2 quarters.
  • Jana Partners's Neurocrine Biosciences position peaked at $7.02M in Q4 2016.
  • 218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2017.

Based on Jana Partners's 13F filing for Q1 2017, filed 15 May 2017.